Abstract
The pharmacokinetics of a novel peroxisome proliferator-activated receptor-γ agonist, KR-62980, were characterized in vitro with respect to liver metabolic stability, cell permeability, and plasma protein binding and in vivo using Sprague-Dawley rats and ICR mice. The metabolic half-life of 0.1–10 μM KR-62980 was 11.5–15.2 min in rat liver microsomes and 25.8–28.8 min in human liver microsomes. KR-62980 showed high permeability across MDCK cell monolayers, with apparent permeability coefficients of 20.4 × 10−6 to 30.8 × 10−6 cm/sec. The plasma protein binding rate of KR-62980 was 89.4%, and most was bound to serum albumin. After intravenous administration of KR-62980 (2 mg/kg), the systemic clearance was 2.50 L/h/kg, and the volume of distribution at steady-state was 9.16 L/kg. The bioavailability after oral administration was approximately 60.9%. The dose-normalized AUC values were 0.50 ± 0.09, 0.41 ± 0.20, and 0.62 ± 0.08 h·μg/mL after oral administration of 2, 5, and 10 mg/kg KR-62980, respectively, showing no dose-dependency. The in vivo pharmacokinetic parameters in ICR mice were also dose independent. These data suggest that KR-62980 is not significantly dose dependent in rats or mice, although it may disappear rapidly from the systemic circulation via metabolism in the liver.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adams, M., Montague, C. T., Prins, J. B., Holder, J. C., Smith, S. A., Sanders, L., Digby, J. E., Sewter, C. P., Lazar, M. A., Chatterjee, V. K., and O’rahilly, S., Activators of peroxisome proliferator-activated receptor gamma have depotspecific effects on human preadipocyte differentiation. J. Clin. Invest., 100, 3149–3153 (1997).
Artursson, P. and Karlsson, J., Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880–885 (1991).
Braun, A., Hammerle, S., Suda, K., Rothen-Rutishauser, B., Gunthert, M., Kramer, S. D., and Wunderli-Allenspach, H., Cell cultures as tools in biopharmacy. Eur. J. Pharm. Sci., 11Suppl 2, S51–S60 (2000).
Brown, K. K., Henke, B. R., Blanchard, S. G., Cobb, J. E., Mook, R., Kaldor, I., Kliewer, S. A., Lehmann, J. M., Lenhard, J. M., Harrington, W. W., Novak, P. J., Faison, W., Binz, J. G., Hashim, M. A., Oliver, W. O., Brown, H. R., Parks, D. J., Plunket, K. D., Tong, W. Q., Menius, J. A., Adkison, K., Noble, S. A., and Willson, T. M., A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes, 48, 1415–1424 (1999).
Calnek, D. S., Mazzella, L., Roser, S., Roman, J., and Hart, C. M., Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol., 23, 52–57 (2003).
Chen, L. L., Yao, J., Yang, J. B., and Yang, J., Predicting MDCK cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis. Acta Pharmacol. Sin., 26, 1322–1333 (2005).
Choi, Y. H., Kim, S. G., and Lee, M. G., Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J. Pharm. Sci., 95, 2543–2552 (2006).
Chui, P. C., Guan, H. P., Lehrke, M., and Lazar, M. A., PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J. Clin. Invest., 115, 2244–2256 (2005).
Evans, R. M., Barish, G. D., and Wang, Y. X., PPARs and the complex journey to obesity. Nat. Med., 10, 355–361 (2004).
Jung, H., Lee, M. S., Jang, E. J., Ahn, J. H., Kang, N. S., Yoo, S. E., Bae, M. A., Hong, J. H., and Hwang, E. S., Augmentation of PPARgamma-TAZ interaction contributes to the anti-adipogenic activity of KR62980. Biochem. Pharmacol., 78, 1323–1329 (2009).
Kim, K. B., Seo, K. A., Yoon, Y. J., Bae, M. A., Cheon, H. G., Shin, J. G., and Liu, K. H., In vitro metabolism of a novel PPAR gamma agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s. Xenobiotica, 38, 1165–1176 (2008).
Kim, K. R., Lee, J. H., Kim, S. J., Rhee, S. D., Jung, W. H., Yang, S. D., Kim, S. S., Ahn, J. H., and Cheon, H. G., KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. Biochem. Pharmacol., 72, 446–454 (2006a).
Kim, K. Y., Kim, S. S., and Cheon, H. G., Differential antiproliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem. Pharmacol., 72, 530–540 (2006b).
Kim, K. Y., Ahn, J. H., and Cheon, H. G., Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation. Mol. Pharmacol., 72, 674–685 (2007).
Kim, M. S., Song, J. S., Roh, H., Park, J. S., Ahn, J. H., Ahn, S. H., and Bae, M. A., Determination of a peroxisome proliferator-activated receptor gamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-car boxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal., 54, 121–126 (2011).
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., and Nebert, D. W., Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1–18 (2004).
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Red Eagle, A., Vats, D., Brombacher, F., Ferrante, A. W., and Chawla, A., Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature, 447, 1116–1120 (2007).
Rangwala, S. M., Rhoades, B., Shapiro, J. S., Rich, A. S., Kim, J. K., Shulman, G. I., Kaestner, K. H., and Lazar, M. A., Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev. Cell, 5, 657–663 (2003).
Skolnik, S., Lin, X., Wang, J., Chen, X. H., He, T., and Zhang, B., Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J. Pharm. Sci., 99, 3246–3265 (2010).
Won, H. Y., Min, H. J., Ahn, J. H., Yoo, S. E., Bae, M. A., Hong, J. H., and Hwang, E. S., Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation. Biochem. Pharmacol., 79, 888–896 (2010).
Yang, S. H. and Lee, M. G., Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. Biopharm. Drug Dispos., 29, 414–426 (2008).
Ye, J. M., Doyle, P. J., Iglesias, M. A., Watson, D. G., Cooney, G. J., and Kraegen, E. W., Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes, 50, 411–417 (2001).
Zahner, D., Alber, J., and Petzinger, E., Cloning and heterologous expression of the ovine (Ovis aries) P-glycoprotein (Mdr1) in Madin-Darby canine kidney (MDCK) cells. J. Vet. Pharmacol. Ther., 33, 304–311 (2010).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, JS., Kim, MS., Song, J.S. et al. Dose-independent pharmacokinetics of a new peroxisome proliferator-activated receptor-γ agonist, KR-62980, in Sprague-Dawley rats and ICR mice. Arch. Pharm. Res. 34, 2051–2058 (2011). https://doi.org/10.1007/s12272-011-1207-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-1207-8